Claims

1. Use of niraparib in the manufacture of a medicament for the treatment of prostate cancer wherein the medicament is to be administered in a safe and effective amount to a human in need thereof.

2. The use of claim 1, wherein the prostate cancer is a castration-resistant prostate cancer or metastatic castration-resistant prostate cancer.

3. The use of claim 2, wherein the prostate cancer is antiandrogen resistant.

4. The use of claim 3, wherein the human is carrying at least one DNA repair anomaly selected from the group consisting of BRCA-1, BRCA-2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, and ATM.

5. The use of claim 4, wherein the DNA repair anomaly is BRCA-1 or BRCA-2.

6. The use of claim 5, wherein the prostate cancer is castration-resistant prostate cancer.

7. The use of claim 5, wherein the prostate cancer is metastatic castration-resistant prostate cancer.

8. The use of claim 6, wherein niraparib is to be administered in an amount of from 30mg/day to 400mg/day.

9. The use of claim 8, wherein the amount of niraparib to be administered is 300mg/day

10. The use of claim 9, wherein niraparib is to be administered as once daily oral administration in three 100mg oral dosage forms.

11. Use of niraparib in the manufacture of a medicament for the treatment of castration and antiandrogen resistant prostate cancer in a human wherein the medicament is to be administered in three 100mg oral dosage form once daily.